Buy research grade Nirsevimab biosimilar ，anti-MEDI-8897, MEDI8897 antibody

Research Grade Nirsevimab

Catalog #: DVV02802 Specific References (0) DATASHEET

SDS-PAGE for Research Grade Nirsevimab ?>

SEC-HPLC for Research Grade Nirsevimab ?>

Host species: Humanized

Isotype: IgG1, kappa

Applications: Research Grade Biosimilar

Expression system: Mammalian Cells

Overview

Catalog No.

DVV02802

Expression system

Mammalian Cells

Species reactivity

HRSV-A

Host species

Humanized

Isotype

IgG1, kappa

Clonality

Monoclonal

Applications

Research Grade Biosimilar

Target

F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1

Concentration

1.64 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P03420

Form

Liquid

Storage buffer

100 mM Pro-Ac, 20 mM Arg, pH 5.0

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

MEDI-8897, MEDI8897, CAS: 1989556-22-0

Clone ID

Nirsevimab

Note

For research use only. Not suitable for clinical or therapeutic use.

Data Image

Bioactivity

Detects F/Fusion glycoprotein F0 in indirect ELISAs.
SDS-PAGE

SDS PAGE for Nirsevimab
SEC-HPLC

The purity of this product is >95% as determined by SEC-HPLC.
Bioactivity

The nanomolar affinities between each antigen and Nirsevimab, as well as AM14-1, confirm their correct conformations, reflecting their varying degrees of immunogenicity.The "pre-fusogenic" BR30 prepared according to the ResVax (Novavax) methodology (GenBank: QEI22738.1), was included for comparison purpose.Annotations:* : Indicates single-chain mutation variants. # : Denotes mutants containing S46G, S215P, and K465Q.
Data sourced from citation (PMID: 39874917)
Bioactivity

Figure 4. 1G9 and 1D8 bind a similar epitope on Pre-F. (A, B) The competitive binding of Nbs 1G9 and 1D8 with six known epitope-specific antibodies. The values are normalized as competitive rates related to the negative control. Data represent the OD450 values measured and are depicted as the mean ± SD from three independent experiments. (C) The values in squares are the percent binding of the monoclonal antibody (IgG) in the presence of the competing Nbs (His-tag) relative to a mock-competition control. Source data are available online for this figure.
Data sourced from citation (PMID: 41946909)
Bioactivity

BLI profiles of BR38 (A), BR40 (B), and BR42 (C). Each column depicts interactions with Nirsevimab, D25, AM14-1, AM14-2, MPE8, and Palivizumab from top to bottom.
Data sourced from citation (PMID: 39874917)
Bioactivity

The table presents affinity coefficients of BR38, BR40, and BR42 with various mAbs. BR40 shows superior antigenicity, while BR42 demonstrates comparable performance. BR38 exhibits inferior characteristics, notably decreased affinity to AM14.Annotations:# : Denotes mutants containing S46G, A149C-Y458C, S215P and K465Q.
Data sourced from citation (PMID: 39874917)
Bioactivity

Long-term stability evaluation. (A-B) Long-term stability assessment of vaccine bulk solutions stored at 4 ℃, evaluated using (A) Nirsevimab and (B) AM14-1. BR40 and BR42 maintained higher levels of neutralizing epitope activity compared to Standard-1 and BR38, indicating superior long-term stability.
Data sourced from citation (PMID: 39874917)
Bioactivity

(A) Competitive antibody titers against Nirsevimab, showcasing the effective induction of NAbs by BR40 and BR42.
Data sourced from citation (PMID: 39874917)
Bioactivity

Each vaccine bulk solution underwent exposure to conditions of 50 ◦C/70 ◦C or pH 3.5/10.0 for 1 h, followed by evaluation of Site Ø retention using Nirsevimab.Annotations:# : Denotes mutants containing S46G, A149C-Y458C, S215P and K465Q.
Data sourced from citation (PMID: 39874917)

References

Datasheet

Document Download

Research Grade Nirsevimab.pdf

$ 800

Product specifications

1 mg 800 5 mg 2240 25 mg 5820

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here